FDA to take an­oth­er look at Ake­bi­a's re­ject­ed kid­ney drug

Will the sec­ond re­view work out bet­ter than the first? Ake­bia Ther­a­peu­tics said this morn­ing that the FDA is tak­ing an­oth­er look at its com­plete re­sponse let­ter for its po­ten­tial treat­ment for ane­mia due to chron­ic kid­ney dis­ease, which was re­ject­ed last March due to safe­ty con­cerns.

The com­pa­ny, which saw its stock price fall by more than 65% at the time of the re­jec­tion of vadadu­s­tat, said the FDA had re­quest­ed a new tri­al and that the safe­ty ques­tions cen­tered on the drug’s “in­creased risk of throm­boem­bol­ic events, dri­ven by vas­cu­lar ac­cess throm­bo­sis in dial­y­sis pa­tients, and the risk of drug-in­duced liv­er in­jury.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER